European Code Against Cancer, 5th edition - hormone replacement therapy, other common medical therapies and cancer.

Mol Oncol · 2026 · PMC12809475 · PMID 41250966

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

did not reach statistical significanceP = 0.11not close (p > 0.1)

The combined HRT [CEE with medroxyprogesterone acetate (MPA)] was associated with higher breast cancer incidence (HR, 1.28; 95% CI, 1.13–1.45; P < 0.001); breast cancer mortality was 35% higher, although this did not reach statistical significance (HR, 1.35; 95% CI, 0.94–1.95; P = 0.11).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.